VSL#3 Junior Launched for Dietary Management of IBS and UC

VSL#3 JUNIOR 225 billion bacteria packets by Sigma-Tau Pharmaceuticals
VSL#3 JUNIOR 225 billion bacteria packets by Sigma-Tau Pharmaceuticals

VSL#3 JUNIOR, a once-daily, high-potency probiotic medical food for the dietary management of children who suffer from irritable bowel syndrome (IBS) and ulcerative colitis (UC) has been launched by Sigma-Tau Pharmaceuticals. Each packet of VSL#3 JUNIOR contains 225 billion colony-forming units (CFU). Using this high concentration of several different strains of specially selected bacteria, VSL#3 products provide an optimal composition of good bacteria, enhancing the health of the GI tract and aiding in dietary management of IBS.

Clinical research of VSL#3 JUNIOR in the dietary management of IBS and UC has yielded statistically significant results among patients for both designations, and is generally recognized as safe. Moreover, it is the first probiotic medical food that has been studied in a pediatric, randomized, double-blind, placebo-controlled crossover trial for children. VSL#3 formulations have been clinically proven to provide a significant improvement in reducing the discomfort and bloating associated with IBS.

VSL#3 JUNIOR can be mixed into cold drinks, such as water and juice, or foods. It is also gluten-free, Kosher and Halal certified. Each box contains 30 watermelon-flavored packets. It is available nationwide, behind the counter, at participating pharmacies.

In addition to VSL#3 JUNIOR, Sigma-Tau distributes three other formulations for adults: VSL#3 DS prescription-only medical food packets, containing 900 billion bacteria; VSL#3 packets, containing 450 billion bacteria, and; VSL#3 capsules, containing 112.5 billion bacteria.

For more information visit www.vsl3.com or call 1-866-634-2765.